Hilde Furberg, a senior vice president for rare diseases at Genzyme, has been appointed as a non-executive director at BerGenBio AS, a Norway-based oncology company. Ms Furberg has worked for more than 30 years in the pharma and biotech industries including as managing director of Pharmalink A/S where she currently is a member of the board of directors.
Also joining the BerGenBio board, is Stener Kvinnsland, chairman of the board of Oslo University Hospital. Dr Kvinnsland has also been chief executive of the Bergen Hospital Trust.
BerGenBio announced the appointments on 1 September 2015.
Copyright 2015 Evernow Publishing Ltd